Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
(neo)Adjuvant chemotherapy
Bladder cancer
Insurance claim review
Renal pelvis
Survival outcomes
Ureter
Urothelial carcinoma
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
07
12
2022
accepted:
07
02
2023
medline:
8
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
To describe the incidence, management, and survival outcomes of patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical surgery (RS) in France. We relied on a non-interventional real-world retrospective study based on French National Hospitalization Database. Adults with MIUC with a first RS between 2015 and 2020 were selected. Subpopulations of patients with RS performed in 2015 and 2019 (pre-COVID-19) were extracted, according to cancer site: muscle-invasive bladder cancer (MIBC) or upper tract urothelial carcinoma (UTUC). Disease-free and overall survival (DFS, OS - Kaplan-Meier) were assessed on the 2015 subpopulation. Between 2015 and 2020, 21,295 MIUC patients underwent a first RS. Of them, 68.9% had MIBC, 28.9% UTUC, and 2.2% both cancers. Apart from fewer men among UTUC (70.2%) than MIBC patients (90.1%), patients' demographic (mean age ~ 73 years) and clinical characteristics were similar whatever the cancer site or year of first RS. In 2019, RS alone was the most frequent treatment, occurring in 72.3% and 92.6% in MIBC and UTUC, respectively. Between 2015 and 2019, neoadjuvant use rate increased from 13.8% to 22.2% in MIBC, and adjuvant use rate increased from 3.7% to 6.3% in UTUC. Finally, median [95% confidence interval] DFS times were 16.0 [14.0-18.0] and 27.0 [23.0-32.0] months among MIBC and UTUC, respectively. Among patients with resected MIUC annually, RS alone remained the main treatment. Neoadjuvant and adjuvant use increased between 2015 and 2019. Nonetheless, MIUC remains of poor prognosis, highlighting an unmet medical need, notably among patients at high risk of recurrence.
Identifiants
pubmed: 36929410
doi: 10.1007/s00345-023-04335-w
pii: 10.1007/s00345-023-04335-w
pmc: PMC10018592
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1069-1075Informations de copyright
© 2023. The Author(s).
Références
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiol Bladder Cancer Med Sci 8(1):15
Defossez G, Le Guyader-Peyrou S, Uhry Z, Grosclaude P, Remontet L, Colonna M. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Volume 1 - Tumeurs solides. Compléments par localisation tumorale et sous-sites ou sous-types histologiques. Saint-Maurice: Santé Publique France; 2019.
Rouprêt M, Audenet F, Roumiguié M, Pignot G, Masson-Lecomte A, Compérat E, et al. Recommandations françaises du Comité de cancérologie de l’AFU - actualisation 2020–2022 : tumeurs de la voie excrétrice urinaire supérieure. Progrès en Urologie. 2020;30(12, Supplement):S52–77.
Rouprêt M, Pignot G, Masson-Lecomte A, Compérat E, Audenet F, Roumiguié M, et al. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : tumeurs de la vessie. Progrès en Urologie. 2020;30(12, Supplement):S78–135.
Léon P, Seisen T, Rouprêt M (2015Jun) Surgical landscape of radical cystectomy for bladder cancer in France over the last 10 years. World J Urol 33(6):889–890
doi: 10.1007/s00345-014-1352-z
pubmed: 24973047
Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM et al (2021) European Association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79(1):62–79
doi: 10.1016/j.eururo.2020.05.042
pubmed: 32593530
Miyazaki J, Nishiyama H (2017) Epidemiology of urothelial carcinoma. Int J Urol 24(10):730–734
doi: 10.1111/iju.13376
pubmed: 28543959
Thorstenson A, Hagberg O, Ljungberg B, Liedberg F, Jancke G, Holmäng S et al (2016) Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scand J Urol 50(4):292–297
doi: 10.3109/21681805.2016.1158207
pubmed: 27002743
Boudemaghe T, Belhadj I (2017) Data Resource Profile: The French National Uniform Hospital Discharge Data Set Database (PMSI). Int J Epidemiol 46(2):392–392d
doi: 10.1093/ije/dyw359
pubmed: 28168290
Méthode : algorithme cancer [Internet]. [cited 2021 Jun 30]. Available from: https://lesdonnees.e-cancer.fr/Informations/Methodes/Methode-algorithme-cancer2
Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346
doi: 10.1016/0197-2456(96)00075-X
pubmed: 8889347
Public Policy Committee IS of P. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiology and Drug Safety. 2016;25(1):2–10.
Comission Nationale Informatique et Libertés (CNIL) [Internet]. [cited 2022 Jul 7]. Available from: https://www.cnil.fr/
Délibération n° 2018–257 du 7 juin 2018 portant homologation d’une méthodologie de référence relative aux traitements de données nécessitant l’accès pour le compte des personnes produisant ou commercialisant des produits mentionnés au II de l’article L. 5311–1 du code de la santé publique aux données du PMSI centralisées et mises à disposition par l’ATIH par l’intermédiaire d’une solution sécurisée (MR 006) [Internet]. CNIL1818711X Jul 13, 2018. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000037187571
Chu AT, Holt SK, Wright JL, Ramos JD, Grivas P, Yu EY et al (2019) Delays in radical cystectomy for muscle-invasive bladder cancer. Cancer 125(12):2011–2017
doi: 10.1002/cncr.32048
pubmed: 30840335
Macleod LC, Fam MM, Yabes JG, Hale NE, Turner RM, Lopa SH et al (2020) Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Genitourin Cancer 18(3):201-209.e2
doi: 10.1016/j.clgc.2019.12.011
pubmed: 31917172
Colombel, M., Soloway, M., Akaza, H., Bö Hle D, A., Palou, J., Buckley, R., Lamm, D., Brausi,. Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. European Urology Supplements. 2008;
Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P et al (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur Urol 63(2):234–241
doi: 10.1016/j.eururo.2012.07.033
pubmed: 22877502
Seisen T, Mari A, Campi R, Peyronnet B, Bensalah K, Rioux-Leclercq N et al (2021) Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. Eur Urol Focus 7(5):1075–1083
doi: 10.1016/j.euf.2020.10.004
pubmed: 33463527
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011Jun 10) Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 29(17):2432–2438
doi: 10.1200/JCO.2011.34.8433
pubmed: 21555688
Witjes JA, Bruins HM, Cathomas R, Compérat E, cowan NC, Efstathiou JA, et al. EAU Guidelines on Muscle-invasive and metastatic bladder Cancer [Internet]. The Netherlands: European Association of Urologu; 2021 [cited 2021 Apr 30] p. 94. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2021.pdf
Roupret M, Babjuk M, Burger M, Compérat E, Cowan NC, Gontero P, et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma [Internet]. The Netherlands: European Association of Urologu; 2021 [cited 2021 Apr 30] p. 38. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Upper-Urinary-Tract-Urothelial-Carcinoma-2021.pdf
Drakaki A, Pantuck A, Mhatre SK, Dhillon PK, Davarpanah N, Degaonkar V et al (2021) “Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urol Oncol: Seminars Origin Investig 39(1):76.e15-76.e22
doi: 10.1016/j.urolonc.2020.07.011
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet 395(10232):1268–1277
doi: 10.1016/S0140-6736(20)30415-3
ALD n° 30 - Cancer de la vessie [Internet]. Haute Autorité de Santé. [cited 2022 Sep 16]. Available from: https://www.has-sante.fr/jcms/c_969326/fr/ald-n-30-cancer-de-la-vessie
Cagiannos I, Morash C (2009) Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J 3(6 Suppl 4):S237–S242
pubmed: 20019993
pmcid: 2792448
Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76–86
doi: 10.1016/S1470-2045(14)71160-X
pubmed: 25498218
Ge P, Wang L, Lu M, Mao L, Li W, Wen R et al (2018) Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis. Sci Rep 8(1):7543
doi: 10.1038/s41598-018-26002-6
pubmed: 29765120
pmcid: 5954122
SPF. Où meurt-on en France ? Analyse des certificats de décès (1993–2008) [Internet]. [cited 2022 Jul 11]. Available from: https://www.santepubliquefrance.fr/notices/ou-meurt-on-en-france-analyse-des-certificats-de-deces-1993-2008